Synairgen plc (LON:SNG)‘s stock had its “corporate” rating reiterated by equities researchers at FinnCap in a research note issued on Tuesday. They presently have a GBX 137 ($1.70) price objective on the stock.

Separately, N+1 Singer reduced their price target on shares of Synairgen plc from GBX 47 ($0.58) to GBX 46 ($0.57) and set a “buy” rating on the stock in a research report on Thursday, September 22nd.

Shares of Synairgen plc (LON:SNG) opened at 14.01 on Tuesday. The stock’s 50 day moving average is GBX 18.81 and its 200 day moving average is GBX 28.20. The stock’s market cap is GBX 12.80 million. Synairgen plc has a 52 week low of GBX 14.01 and a 52 week high of GBX 38.00.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The correct version of this piece can be read at

Synairgen plc Company Profile

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease.

Receive News & Stock Ratings for Synairgen plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen plc and related stocks with our FREE daily email newsletter.